Varlilumab is under clinical development by Celldex Therapeutics and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Varlilumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Varlilumab overview

Varlilumab (CDX-1127) is under development for the treatment of cancer including solid tumors, hematologic cancers such as mantle cell lymphoma, marginal zone B cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, primary lymphoma of the central nervous system and glioblastoma. The drug candidate is administered intravenously. The drug candidate is a fully human monoclonal antibody targeting CD27. It was also under development for triple negative breast cancer, bladder cancer, hormone-refractory prostate adenocarcinoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, metastatic melanoma, metastatic clear cell renal cell carcinoma (second line therapy), non-small cell lung cancer, melanoma, head and neck cancer squamous cell carcinoma, epithelial ovarian, fallopian tube cancer, colorectal adenocarcinoma, metastatic renal cell carcinoma and B cell lymphomas.

Celldex Therapeutics overview

Celldex Therapeutics (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell carcinoma. It operates a manufacturing facility in Massachusetts, the US, and research laboratories in Massachusetts, New Jersey, and Connecticut. Celldex is headquartered in Hampton, New Jersey, the US.

For a complete picture of Varlilumab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.